Dr Łukasz Witucki is a molecular biologist and postdoctoral researcher at the Poznań University of Life Sciences, Poland. His research focuses on the molecular mechanisms linking homocysteine metabolism, epigenetic regulation, mTOR signaling, autophagy, and neurodegenerative diseases, particularly Alzheimer’s disease.
He received his PhD in Biology from the Institute of Bioorganic Chemistry, Polish Academy of Sciences, in 2023. Since 2024, he has been conducting postdoctoral research on the role of bleomycin hydrolase (BLMH) in homocysteine metabolism and Alzheimer’s disease pathogenesis.
His major scientific contributions include the identification of molecular and epigenetic mechanisms by which hyperhomocysteinemia and deficiencies of CBS, PON1, or BLMH dysregulate mTOR signaling and inhibit autophagy. His work demonstrated that these conditions lead to downregulation of the histone demethylase PHF8, increased H4K20me1 occupancy at the mTOR gene, mTOR activation, impaired autophagic clearance, and accumulation of amyloid-β. He also showed that PHF8 deficiency promotes amyloidogenic processing through epigenetic regulation of BACE1 and PSEN1. In addition, he identified a microRNA-mediated mechanism linking homocysteine metabolites to PHF8 dysregulation. His research has contributed to understanding how disturbances in one-carbon metabolism and epigenetic regulation drive neurodegeneration and may reveal novel therapeutic targets for Alzheimer’s disease.
Dr Łukasz Witucki is a molecular biologist and postdoctoral researcher at the Poznań University of Life Sciences, Poland. His research focuses on the molecular mechanisms linking homocysteine metabolism, epigenetic regulation, mTOR signaling, autophagy, and neurodegenerative diseases, particularly Alzheimer’s disease.
He received his PhD in Biology from the Institute of Bioorganic Chemistry, Polish Academy of Sciences, in 2023. Since 2024, he has been conducting postdoctoral research on the role of bleomycin hydrolase (BLMH) in homocysteine metabolism and Alzheimer’s disease pathogenesis.
His major scientific contributions include the identification of molecular and epigenetic mechanisms by which hyperhomocysteinemia and deficiencies of CBS, PON1, or BLMH dysregulate mTOR signaling and inhibit autophagy. His work demonstrated that these conditions lead to downregulation of the histone demethylase PHF8, increased H4K20me1 occupancy at the mTOR gene, mTOR activation, impaired autophagic clearance, and accumulation of amyloid-β. He also showed that PHF8 deficiency promotes amyloidogenic processing through epigenetic regulation of BACE1 and PSEN1. In addition, he identified a microRNA-mediated mechanism linking homocysteine metabolites to PHF8 dysregulation. His research has contributed to understanding how disturbances in one-carbon metabolism and epigenetic regulation drive neurodegeneration and may reveal novel therapeutic targets for Alzheimer’s disease.